The Latest News
Exagen Becomes a Portfolio Company of Tullis Growth Fund, L.P.
Exagen Diagnostics, a portfolio company of Tullis-Dickerson Captial Focus III, L.P. (TD3), was recently invested by Tullis Growth Fund, L.P. (TGF). The company has developed proprietary diagnostics, established a clinical laboratory and built a specialty sales and marketing force to reach physicians who diagnose and treat patients suffering from autoimmune rheumatic diseases including Lupus. Exagen has achieved a run rate in revenue approaching $20 million.
Jim Tullis, Founder of Tullis Health Investors and member of Board of Directors of Exagen said: “Exagen is an investment that fits our guardrails and investment focus tightly. Led by an experienced management team, Exagen has rapidly built a meaningful sales base in a large and growing medical market. We welcome the company to the TGF portfolio.”
Exagen has filed an S-1 for a possible IPO and hopes to achieve public status later in 2015.